Tag: 50681-25-9

50681-25-9,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50681-25-9,4-Pyridazinecarboxylic Acid,as a common compound, the synthetic route is as follows.

Example 47-1 : Synthesis of (2R,4S)-5-Biphenyl-4-yl-2-methyl-4-[(pyridazine-4- carbonyl)-amino]-pentanoic acid; To a stirred solution of pyridazine-4-carboxylic acid (21 mg, 0.17 mmol) in DMF (6 ml_) is added HOBT (26 mg, 0.17 mmol) and HBTU (65 mg, 0.17 mmol) and the mixture is stirred at room temperature for 10 minutes. (2R,4S)-4-Amino-5-biphenyl-4-yl-2-methyl-pentanoic acid ethyl ester hydrochloride (50 mg, 0.14 mmol) and DIEA (42 mg, 0.56 mmol) are added. After stirring the mixture at room temperature for 18 hours, water is added and the mixture is extracted three times with ethyl acetate. The combined organic layers are washed with water and brine then is dried over magnesium sulfate. The solvent is removed under reduced pressure to give the title compound; HPLC retention time 1.19 minutes (condition C); MS 390.3 (M+H); 1 H NMR (400 MHz, DMSO-d6): ? ppm 1 .08-1 .10 (d, J=7.07 Hz, 3H), 1 .59-1 .66 (m, 1 H), 1 .88-1 .95 (m, 1 H), 2.46-2.53 (m, 1 H), 2.85-2.87 (d, J=6.82 Hz, 2H), 4.22- 4.30 (m, 1 H), 7.29-7.32 (m, 2H), 7.33-7.36 (m, 1 H), 7.42-7.46 (m, 2H), 7.57-7.59 (m, 2H), 7.62-7.65 (m, 2H), 7.91 -7.93 (q, J=2.27 Hz, 1 H), 8.76-8.78 (d, J=8.59 Hz, 1 H), 9.41 -9.43 (m, 1 H), 9.45-9.46 (m, 1 H), 12.09 (s, 1 H).

As the paragraph descriping shows that 50681-25-9 is playing an increasingly important role.

Reference£º
Patent; NOVARTIS AG; COPPOLA, Gary Mark; IWAKI, Yuki; KARKI, Rajeshri Ganesh; KAWANAMI, Toshio; KSANDER, Gary Michael; MOGI, Muneto; SUN, Robert; WO2010/136474; (2010); A2;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50681-25-9,4-Pyridazinecarboxylic Acid,as a common compound, the synthetic route is as follows.

Intermediate 29 Step A: A solution of pyridazine-4-carboxylic acid (92.5 mg, 0.754) and 2-(7-aza- 1H- benzotriazole-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate (283 mg, 0.745 mmol) in 1 : 1 CH2C12/DMF (10 mL) was treated with NEt3 (108 mg, 1.06 mmol) and stirred for 10 min. A solution of 1-28 (224 mg, 0.56 mmol) in 1: 1 CH2C12/DMF (10 mL) was then added and the mixture was stirred for lh (reaction completion monitored by LC/MS). The solvent was evaporated under reduced pressure and the residue was dissolved in CH2CI2 (4 mL), treated with Na2CC>3 (178 mg, 1.68 mmol) and stirred for 3 minutes. The mixture was then purified by column chromatography (MeOH in CH2CI2, 0% to 10%) to afford (R)-tert-buty 3-(7-chloro-6-methoxy-2-(pyridazine-4- carboxamido)-lH-benzo[d]imidazol-l-yl)azepane-l-carboxylate (I-29a). MS calculated for C24H30CIN6O4 (M+H+) 501.19, found 501.2.

The synthetic route of 50681-25-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; IRM LLC; LELAIS, Gerald; EPPLE, Robert; MARSILJE, III, Thomas H.; MICHELLYS, Pierre-Yves; MCNEILL, Matthew H.; LONG, Yun; LU, Wenshuo; CHEN, Bei; BURSULAYA, Badry; JIANG, Songchun; WO2013/184757; (2013); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50681-25-9,4-Pyridazinecarboxylic Acid,as a common compound, the synthetic route is as follows.

Intermediate 29 Step A: A solution of pyridazine-4-carboxylic acid (92.5 mg, 0.754) and 2-(7-aza- 1H- benzotriazole-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate (283 mg, 0.745 mmol) in 1 : 1 CH2C12/DMF (10 mL) was treated with NEt3 (108 mg, 1.06 mmol) and stirred for 10 min. A solution of 1-28 (224 mg, 0.56 mmol) in 1: 1 CH2C12/DMF (10 mL) was then added and the mixture was stirred for lh (reaction completion monitored by LC/MS). The solvent was evaporated under reduced pressure and the residue was dissolved in CH2CI2 (4 mL), treated with Na2CC>3 (178 mg, 1.68 mmol) and stirred for 3 minutes. The mixture was then purified by column chromatography (MeOH in CH2CI2, 0% to 10%) to afford (R)-tert-buty 3-(7-chloro-6-methoxy-2-(pyridazine-4- carboxamido)-lH-benzo[d]imidazol-l-yl)azepane-l-carboxylate (I-29a). MS calculated for C24H30CIN6O4 (M+H+) 501.19, found 501.2.

The synthetic route of 50681-25-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; IRM LLC; LELAIS, Gerald; EPPLE, Robert; MARSILJE, III, Thomas H.; MICHELLYS, Pierre-Yves; MCNEILL, Matthew H.; LONG, Yun; LU, Wenshuo; CHEN, Bei; BURSULAYA, Badry; JIANG, Songchun; WO2013/184757; (2013); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem